Payment overview · 2025
General Payments
$227.50
13 reported records · 10 companies
Healthcare provider profile · identity verified
Brett Wergin, MD
Allopathic & Osteopathic Physicians|Family Medicine · LINCOLN, NE · NPI 1912388927
Verified facts
What the public records show
CMS Open Payments records show Brett Wergin, MD received $227.50 in general payments during 2025 across 13 reported records.
Dexcom, Inc. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.42 | 17.3% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $32.93 | 14.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.07 | 14.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.07 | 10.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.60 | 10.4% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $18.59 | 8.2% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.04 | 6.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.55 | 6.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.66 | 6.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.57 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $227.50 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.42 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.07 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| Kcentra Normalized: kcentra |
Biological | CSL Behring | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 126 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 494 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 72 |
| Losartan Potassium | Losartan Potassium | 392 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 366 | 75 |
| Lisinopril | Lisinopril | 351 | 78 |
| Potassium Chloride | Potassium Chloride | 318 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 72 |
| Gabapentin | Gabapentin | 291 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 62 |
| Metformin Hcl | Metformin Hcl | 226 | 57 |
| Sertraline Hcl | Sertraline Hcl | 194 | 40 |
| Omeprazole | Omeprazole | 190 | 46 |
| Jardiance | Empagliflozin | 185 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 35 |
| Furosemide | Furosemide | 144 | 40 |
| Meloxicam | Meloxicam | 138 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 30 |
| Warfarin Sodium | Warfarin Sodium | 134 | 15 |
| Simvastatin | Simvastatin | 128 | 30 |
| Ozempic | Semaglutide | 126 | 16 |
| Xarelto | Rivaroxaban | 125 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 21 |
| Tramadol Hcl | Tramadol Hcl | 99 | 28 |
| Allopurinol | Allopurinol | 94 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 22 |
| Finasteride | Finasteride | 89 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 22 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 82 | 15 |
| Famotidine | Famotidine | 75 | 16 |
| Trulicity | Dulaglutide | 70 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 15 |
| Pregabalin | Pregabalin | 67 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 17 |
| Buspirone Hcl | Buspirone Hcl | 61 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 16 |
| Prednisone | Prednisone | 59 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 13 |
| Carvedilol | Carvedilol | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 11 |
| Torsemide | Torsemide | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 14 |
| Montelukast Sodium | Montelukast Sodium | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Alprazolam | Alprazolam | 45 | 12 |
| Cephalexin | Cephalexin | 45 | 33 |
| Naproxen | Naproxen | 45 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | 15 |
| Spironolactone | Spironolactone | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 15 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 20 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | 11 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 16 |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Letrozole | Letrozole | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $227.50 · 13 records | Dexcom, Inc. | CAPLYTA, Dexcom G6 Transmitter, EVENITY, Fluad, Flucelvax, Kcentra, Kerendia, Ozempic, PAXLOVID, PROLIA, REXULTI, Rybelsus, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error